Trials / Terminated
TerminatedNCT00556075
Safety and Efficacy Study to Evaluate Proellex in the Treatment of Premenopausal Women With Symptomatic Endometriosis
A Phase II, Three-Arm, Parallel Design, Dose-Ranging Placebo-Controlled, Randomized, Double-Blind, Multicenter Study Evaluating the Safety and Efficacy of Proellex in the Treatment of Premenopausal Women With Symptomatic Endometriosis
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 67 (actual)
- Sponsor
- Repros Therapeutics Inc. · Industry
- Sex
- Female
- Age
- 18 Years – 48 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether Proellex is safe and effective for the treatment of symptomatic endometriosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Proellex 25 mg | 1 capsule daily for 4 months |
| DRUG | Placebo | 1 capsule daily for 4 months |
| DRUG | Proellex 50 mg | 2 capsules daily for 4 months |
Timeline
- Start date
- 2007-11-01
- Primary completion
- 2009-05-01
- Completion
- 2009-07-01
- First posted
- 2007-11-09
- Last updated
- 2014-08-25
- Results posted
- 2014-08-25
Locations
17 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00556075. Inclusion in this directory is not an endorsement.